Raya Massoud, MD
Neurology · Frederick, MDNPI 1831370063
Payments from drug & device makers
Across 38 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$95
- Amgen$95
- Johnson & Johnson$63
- Genentech USA, Inc.$53
- Merck$47
- Supernus Pharmaceuticals, Inc.$43
- plus $380 from 17 others
What the payments were for
- Food & beverage$775100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $95 |
| Amgen | 5 | $95 |
| Johnson & Johnson(2 entities) | 3 | $63 |
| Genentech USA, Inc. | 3 | $53 |
| Merck | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| Life Molecular Imaging Ltd | 1 | $43 |
| GSK | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Exelixis Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Morphosys, US Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| AbbVie | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Seagen Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$775 in reported general payments places this provider in the 35th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 29 | $2,420 |
| Memantine Hcl | 84 | $2,406 |
| Donepezil Hcl | 162 | $1,937 |
| Levetiracetam | 27 | $1,078 |
| Gabapentin | 71 | $1,024 |
| Duloxetine Hcl | 29 | $836 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 35 | $672 |
| Bupropion Hcl SrBupropion Hcl | 17 | $434 |
| Ropinirole Hcl | 12 | $332 |
| Escitalopram Oxalate | 19 | $314 |
| Mirtazapine | 12 | $215 |
| Sertraline Hcl | 27 | $144 |
| Trazodone Hcl | 11 | $139 |
Paid to pharmacies, not to this prescriber.
Other neurology in Frederick
- Boyd DwyerFrederick$214K
- Jose MasdeuBethesda$5.8M
- Ellen MowryBaltimore$5.7M
- Daniel BeckerLutherville$4.2M
- Michael PolydefkisBaltimore$4.1M
- Pavel KleinBethesda$3.2M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.